4.7 Article

PRRT2 mutations A major cause of paroxysmal kinesigenic dyskinesia in the European population

Journal

NEUROLOGY
Volume 79, Issue 2, Pages 170-174

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31825f06c3

Keywords

-

Funding

  1. INSERM through the French Dystonia Network
  2. MERZ-Pharma
  3. Djillali Mehri
  4. Lundbeck
  5. Teva
  6. Novartis
  7. Boeringher-Ingelheim
  8. Abbott Products
  9. Direction Generale de l'Organisation des soins (DGOS)
  10. Institut National de la Sante et de la Recherche Medicale (INSERM)
  11. Michael J. Fox Foundation for Parkinson Research
  12. French association for Essential Tremor (APTES)
  13. UCB Pharma
  14. Swiss National Foundation
  15. French Ministry of Research
  16. ARSla charity
  17. DHOS-INSERM
  18. ANR (French National Institutes)
  19. AMADYS
  20. Alliance France Dystonie (patients' associations)
  21. French Agency for Research
  22. Programme Hospitalier de Recherche Clinique
  23. Michael J. Fox Foundation
  24. French Association Against Myopathies (non-profit foundations)
  25. INSERM (COSSEC)
  26. AP-HP (DRC-PHRC)
  27. Fondation pour la Recherche Medicale
  28. Dystonia Coalition (Pilot project)
  29. IPSEN
  30. TEVA Pharma
  31. Dystonia Coalition
  32. Dystonia Medical Research Foundation
  33. Movement Disorders Society
  34. World Federation of Neurology Association of Parkinsonism and Related Disorders
  35. Bachmann and Strauss Foundation

Ask authors/readers for more resources

Objective: Paroxysmal kinesigenic dyskinesia (PKD) is a rare disorder characterized by recurrent attacks of hyperkinetic movements. PKD can be isolated or associated with benign infantile seizures as part of the infantile convulsions with choreoathetosis (ICCA) syndrome. Mutations in the PRRT2 gene were recently identified in patients with PKD and ICCA. We studied the prevalence of PRRT2 mutations and characteristics of the patients in a European population of patients with PKD and ICCA. Methods: Patients were recruited through the 1996-2011 database of our DNA bank, to which physicians refer DNA with a putative diagnosis and clinical information. Two movement disorders experts reviewed the information on patients with a putative diagnosis of PKD. Patients who fulfilled the criteria for PKD and ICCA were included. The PRRT2 coding sequence was analyzed by direct sequencing. Results: Among 42 index cases of unrelated families referred with a putative diagnosis of PKD, a total of 34 patients, including 32 with isolated PKD and 2 with ICCA, were selected for genetic analysis. Mutations introducing premature termination codons were identified in 22 of 34 patients including 13 of 14 families and 9 of 20 patients with sporadic cases. The previously described c.649dupC/pArg217ProfsX8 and c.629dupC/pAla211SerfsX14 were present, respectively, in 17 patients and 1 patient; we also report 3 novel mutations: c.649delC/pArg217GlufsX12 in 2 patients, and c.562C>T/pGln188X and c. 649C>T/pArg217X, each in 1 patient. The group with mutations was characterized by a younger age at onset (9 years) compared with the patients without mutations (15 years; p < 0.01). Conclusion: Mutations in PRRT2 are a major cause of PKD in familial and sporadic cases in the European population. Neurology (R) 2012;79:170-174

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available